Baxter International, a leading global medical products company, acquired Cheetah Medical, a leading provider of non-invasive hemodynamic monitoring technologies. The transaction consists of an upfront cash consideration of $190m, with potential for an additional $40m based on clinical and commercial milestones. The agreement demonstrates Baxter's ongoing commitment to improving clinical outcomes with an established patient monitoring technology to better inform and guide clinicians' treatment decisions. Cheetah Medical is a natural adjacency for Baxter, given Baxter's longstanding leadership in infusion systems and intravenous (IV) solutions, breadth of knowledge in fluid management, and strong presence in critical care and IV therapy. "The robust capabilities and innovative monitoring technologies we will gain with the acquisition of Cheetah Medical will be additional strategic growth drivers as we work to eliminate preventable harm and enable personalized therapy for hospitalized patients around the world,” David Ferguson, general manager, Medication Delivery, Baxter.